Standard BioTools Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
$0.03next fiscal year
Monitoring Framework
Key Performance Indicators
Revenue from Continuing Operations Quarterly21.1MTarget: 80000000 to 85000000
Consumables Revenue Quarterly11M
Adjusted EBITDA Loss Quarterly-3.1MTarget: Positive Adjusted EBITDA exiting 2026
Watch Items
- Nasdaq Minimum Bid-Price Deficiency Notice ComplianceTrigger: Share price below $1.00Action: Regain compliance by October 19, 2026, or face potential delisting.
- Pending All-Stock Merger with Treeline BiosciencesTrigger: Stockholder and regulatory approvalsAction: Complete the transaction in the second half of 2026 to transition into Treeline Biosciences (Nasdaq: TRLN).
- Divestiture or Strategic Options for Legacy Mass Cytometry and Microfluidics BusinessesTrigger: Execution of legacy asset monetizationAction: Pursue independent options or wind-down to maximize value for legacy stockholders via Contingent Value Rights (CVRs).
Research as of 19 Jun 2026